Royalty Pharma (RPRX) News Today $33.42 +0.09 (+0.27%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$33.20 -0.22 (-0.66%) As of 02/21/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Bryn Mawr Capital Management LLCBryn Mawr Capital Management LLC raised its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 564.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 56,464 shares of the biopharmaceutical company's stock after buyingFebruary 21 at 4:36 AM | marketbeat.comRoyalty Pharma (NASDAQ:RPRX) Sets New 1-Year High - What's Next?Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year High - Time to Buy?February 20 at 11:32 AM | marketbeat.comVan ECK Associates Corp Increases Holdings in Royalty Pharma plc (NASDAQ:RPRX)Van ECK Associates Corp raised its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 25.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 127,140 shares of the biopharmaceutical company's stock aFebruary 20 at 3:16 AM | marketbeat.com2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall StreetFebruary 19 at 9:54 AM | msn.comAllspring Global Investments Holdings LLC Boosts Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)Allspring Global Investments Holdings LLC increased its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 303.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 539,995 shares of the bFebruary 18, 2025 | marketbeat.comBaillie Gifford & Co. Lowers Stake in Royalty Pharma plc (NASDAQ:RPRX)Baillie Gifford & Co. cut its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 12.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,134,516 shares of the bioFebruary 17, 2025 | marketbeat.comRoyalty Pharma plc (RPRX) Stock ForecastsFebruary 14, 2025 | ca.finance.yahoo.comRoyalty Pharma (RPRX) to Release Quarterly Earnings on ThursdayRoyalty Pharma (NASDAQ:RPRX) will be releasing earnings before the market opens on Thursday, February 20, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=660029)February 13, 2025 | marketbeat.comRoyalty Pharma: Delivering Growth With A Positive Story AheadFebruary 12, 2025 | seekingalpha.comRoyalty Pharma plc: Royalty Pharma Announces R&D Funding Collaboration With BiogenFebruary 12, 2025 | finanznachrichten.deRoyalty Pharma plc (RPRX): A Cheap Biotech Stock to Invest In NowFebruary 12, 2025 | msn.comRoyalty Pharma plc (NASDAQ:RPRX) Q4 2024 Earnings Call TranscriptFebruary 12, 2025 | insidermonkey.comRoyalty Pharma Announces R&D Funding Collaboration With BiogenFebruary 12, 2025 | globenewswire.comSumitomo Mitsui Trust Group Inc. Lowers Holdings in Royalty Pharma plc (NASDAQ:RPRX)Sumitomo Mitsui Trust Group Inc. reduced its stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 5.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 952,723 shares of the biopharmaceutical comFebruary 12, 2025 | marketbeat.comRoyalty Pharma (NASDAQ:RPRX) Reaches New 12-Month High After Strong EarningsFebruary 12, 2025 | americanbankingnews.comRoyalty Pharma plc (RPRX) Q4 2024 Earnings Call TranscriptFebruary 11, 2025 | seekingalpha.comRoyalty Pharma plc 2024 Q4 - Results - Earnings Call PresentationFebruary 11, 2025 | seekingalpha.comRoyalty Pharma (NASDAQ:RPRX) Hits New 52-Week High on Earnings BeatRoyalty Pharma (NASDAQ:RPRX) Reaches New 1-Year High Following Better-Than-Expected EarningsFebruary 11, 2025 | marketbeat.comRoyalty Pharma reports Q4 portfolio receipts of $742MFebruary 11, 2025 | markets.businessinsider.comRoyalty Pharma sees FY25 portfolio receipts $2.9B-$3.05BFebruary 11, 2025 | markets.businessinsider.comRoyalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue EstimatesFebruary 11, 2025 | msn.comRoyalty Pharma (NASDAQ:RPRX) Posts Earnings Results, Beats Estimates By $0.16 EPSRoyalty Pharma (NASDAQ:RPRX - Get Free Report) announced its earnings results on Tuesday. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.65% and a net margin of 50.53%.February 11, 2025 | marketbeat.comRoyalty Pharma Reports Q4 and Full Year 2024 ResultsFebruary 11, 2025 | globenewswire.comabrdn plc Has $2.28 Million Position in Royalty Pharma plc (NASDAQ:RPRX)abrdn plc trimmed its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 14.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 89,667 shares of the biopharmaceutical company's stocFebruary 11, 2025 | marketbeat.comRoyalty Pharma Earnings: What To Look For From RPRXFebruary 10, 2025 | msn.comIs Now The Time To Put Royalty Pharma (NASDAQ:RPRX) On Your Watchlist?February 10, 2025 | finance.yahoo.comRoyalty Pharma plc (NASDAQ:RPRX) Shares Sold by Lecap Asset Management Ltd.Lecap Asset Management Ltd. trimmed its holdings in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 70.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,789 shares of the biopharmaceutical company's stock after sellingFebruary 9, 2025 | marketbeat.comRoyalty Pharma plc (NASDAQ:RPRX) Receives Consensus Recommendation of "Buy" from AnalystsRoyalty Pharma plc (NASDAQ:RPRX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the seven research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued aFebruary 6, 2025 | marketbeat.comRoyalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Paragon Capital Management Inc.Paragon Capital Management Inc. grew its position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 328.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 70,339 shares of the biopharmaceutical company's stock after acquiring an additionFebruary 5, 2025 | marketbeat.comRoyalty Pharma (RPRX) to Release Quarterly Earnings on TuesdayRoyalty Pharma (NASDAQ:RPRX) will be releasing earnings before the market opens on Tuesday, February 11. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=660029)February 4, 2025 | marketbeat.comRoyalty Pharma plc (NASDAQ:RPRX) Shares Sold by Mediolanum International Funds LtdMediolanum International Funds Ltd decreased its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 47.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 140,342 shares of the biopharmaceutical companFebruary 2, 2025 | marketbeat.comRoyalty Pharma plc (NASDAQ:RPRX) Shares Bought by Inlet Private Wealth LLCInlet Private Wealth LLC increased its position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 25.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 236,740 shares of the biopharmaceutical company'sFebruary 1, 2025 | marketbeat.comChina Universal Asset Management Co. Ltd. Acquires 8,018 Shares of Royalty Pharma plc (NASDAQ:RPRX)China Universal Asset Management Co. Ltd. raised its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 9.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 94,208 shares of the biopharmaceutical company's stocFebruary 1, 2025 | marketbeat.comRobeco Institutional Asset Management B.V. Raises Stock Position in Royalty Pharma plc (NASDAQ:RPRX)Robeco Institutional Asset Management B.V. raised its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 8.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 548,761 shares of the biopharFebruary 1, 2025 | marketbeat.comManning & Napier Advisors LLC Lowers Position in Royalty Pharma plc (NASDAQ:RPRX)Manning & Napier Advisors LLC decreased its position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 39.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 81,054 shares of the biophaJanuary 31, 2025 | marketbeat.comKearns & Associates LLC Buys New Shares in Royalty Pharma plc (NASDAQ:RPRX)Kearns & Associates LLC purchased a new stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 17,685 shares of the biopharmaceutical company's stock, valJanuary 30, 2025 | marketbeat.comSwedbank AB Raises Stake in Royalty Pharma plc (NASDAQ:RPRX)Swedbank AB boosted its position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 10.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,164,170 shares of the biopharmaceutical companyJanuary 29, 2025 | marketbeat.comRoyalty Pharma plc Closes $511 Million Monetization Transaction for MorphoSys Development Funding Bonds, Totaling $530 Million ProceedsJanuary 29, 2025 | quiverquant.comRoyalty Pharma Announces Sale of MorphoSys Development Funding BondsJanuary 29, 2025 | globenewswire.comRoyalty Pharma (NASDAQ:RPRX) Sees Large Volume Increase - Here's WhyRoyalty Pharma (NASDAQ:RPRX) Sees Large Volume Increase - Still a Buy?January 28, 2025 | marketbeat.comRoyalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025January 28, 2025 | globenewswire.comRoyalty Pharma (NASDAQ:RPRX) Reaches New 52-Week High - What's Next?Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week High - What's Next?January 27, 2025 | marketbeat.com1834 Investment Advisors Co. Takes $242,000 Position in Royalty Pharma plc (NASDAQ:RPRX)1834 Investment Advisors Co. acquired a new position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 9,500 shares of the biopharmaceutical company's stock, valuedJanuary 27, 2025 | marketbeat.comAssenagon Asset Management S.A. Purchases Shares of 19,068 Royalty Pharma plc (NASDAQ:RPRX)Assenagon Asset Management S.A. acquired a new position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 19,068 shares of the biopharmaceutical company's stJanuary 26, 2025 | marketbeat.comRoyalty Pharma’s Internalization and Promising Catalysts Lead to Buy Rating with Attractive ValuationJanuary 25, 2025 | markets.businessinsider.comImpact Partnership Wealth LLC Takes $467,000 Position in Royalty Pharma plc (NASDAQ:RPRX)Impact Partnership Wealth LLC purchased a new position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 18,323 shares of the biopharmaceuJanuary 24, 2025 | marketbeat.comWhy Is Andreas Halvorsen Bullish On Royalty Pharma plc (RPRX) Now?January 23, 2025 | msn.comCytokinetics started at buy by Stifel, aficamten highlightedJanuary 22, 2025 | seekingalpha.comOverbrook Management Corp Has $3.02 Million Stock Position in Royalty Pharma plc (NASDAQ:RPRX)Overbrook Management Corp lessened its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 16.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 118,408 shares of the biopharmaceutical company's stock after selling 22,500 shares during theJanuary 20, 2025 | marketbeat.comRoyalty Pharma plc (RPRX): Analysts Recommend This 52-Week High Stocks NowJanuary 16, 2025 | msn.com Get Royalty Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address RPRX Media Mentions By Week RPRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RPRX News Sentiment▼1.200.88▲Average Finance News Sentiment RPRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RPRX Articles This Week▼66▲RPRX Articles Average Week Get Royalty Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Zoetis News Today Jazz Pharmaceuticals News Today Corcept Therapeutics News Today Perrigo News Today Supernus Pharmaceuticals News Today Pacira BioSciences News Today Omeros News Today Nektar Therapeutics News Today Assembly Biosciences News Today Cumberland Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RPRX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Royalty Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RPRX Stock Alerts